OTC · Biotechnology

Hemostemix Inc (HMTXF) Stock

$0.05 -14.81% OTC: HMTXF Healthcare

Hemostemix, Inc. is a clinical-stage biotechnology company, which is focused on developing and commercializing a proprietary autologous cell therapy to treat ischemic diseases.

Valuation

MetricValue
Price$0.05
Market Cap$9.22M
P/E Ratio-2.53
P/B Ratio-1.79
P/S Ratio0.00
EPS (TTM)$-0.03
52-Week High$0.10
52-Week Low$0.04
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE80.07%
ROA-991.47%
ROCE413.73%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity-0.66
Current Ratio0.24

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-7.0M$-3.0M$-2.0M$-2.0M$-6.0M
Net Profit$-6.0M$-5.0M$-3.0M$-3.0M$-5.0M
EPS$-0.11$-0.07$-0.03$-0.03$-0.03
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$1.0M$0$0$1.0M$1.0M
Total Liabilities$6.0M$7.0M$8.0M$8.0M$6.0M
Cash$0$0$0$1.0M$1.0M
Borrowings$1.0M$4.0M$4.0M$5.0M$4.0M

Latest News

Hemostemix Grants Stock Options TMX Newsfile · Jul 22, 2026 Hemostemix Files Commercialization Application for Treatment of Vascular Dementia, Refractory Angina and Pain MT Newswires · Jul 8, 2026 Commercialization Application Filed by Hemostemix for the Treatment of Vascular Dementia, Angina and Pain TMX Newsfile · Jul 8, 2026 Hemostemix Raises C$360,000 in the First Tranche of Private Placement of Share Units MT Newswires · Jun 26, 2026 Hemostemix Closes $360,000 First Tranche of Private Placement TMX Newsfile · Jun 26, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-3.0M$-6.0M$-1.0M$-2.0M$-5.0M
Investing Cash Flow$0$0$0$0$0
Financing Cash Flow$0$0$0$0$0
Net Cash Flow$0$0$0$1.0M$0
Free Cash Flow$-3.0M$-6.0M$-1.0M$-2.0M$-5.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.02
EV / EBITDA-4.00
FCF Yield-47.92%
Quick Ratio0.24
Interest Coverage-10.59
Return 1Y-40.04%
Return 3Y-38.05%
Return 5Y—

Ownership

Insiders Held17.14%
Institutions Held0.00%
Institutions Float Held0.00%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AAPLApple Inc. $313.33 +0.29% 37.72 $4.60T 0.34%
MSFTMicrosoft Corporation $499.99 +0.03% 22.95 $3.71T 0.94%
GOOGLAlphabet Inc. $354.30 -0.96% 27.68 $4.29T 0.23%
AMZNAmazon.com, Inc. $274.48 +0.82% 28.76 $2.95T 0.00%
METAMeta Platforms, Inc. $592.10 +0.37% 21.47 $1.51T 0.35%

About Hemostemix Inc

Hemostemix, Inc. is a clinical-stage biotechnology company, which is focused on developing and commercializing a proprietary autologous cell therapy to treat ischemic diseases. The firm's, ACP-01, lead clinical stage candidate, is an autologous cell therapy for the treatment of critical limb ischemia. The company was founded by Roger Bergersen and Thomas A. Smeenk in 2006 and is headquartered in Calgary, Canada.

Hemostemix Inc is headquartered in CA.

Hemostemix Inc (HMTXF) stock trades at $0.05 with a market capitalization of $9.22M. The stock is valued at a price-to-earnings (P/E) ratio of -2.53, price-to-book of -1.79, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.04 and $0.10, and currently trades 50.0% below its 52-week high.

On profitability, Hemostemix Inc generates a return on equity (ROE) of 80.07% — well above the market average, a sign of a high-quality business, return on capital employed of 413.73%, an operating margin of 0.00%, a net profit margin of 0.00%.

Official website: www.hemostemix.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides